Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

Conditions

• COVID-19

Interventions

• BIOLOGICAL: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
• BIOLOGICAL: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
• BIOLOGICAL: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
• BIOLOGICAL: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
• BIOLOGICAL: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#
• BIOLOGICAL: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
• BIOLOGICAL: Two doses of placebo at the schedule of day 0, 14 #High-dose group#
• BIOLOGICAL: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#

Sponsor

Jiangsu Province Centers for Disease Control and Prevention

Collaborators

• [object Object]
• [object Object]
• [object Object]